David Eric Collins, MD
Neurology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 38 years
- University of Kansas School of Med (Kc/Wich/Sal), 1988
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Collins’s office at (510) 204-8140 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G68739 · Current
Licensed to practise in California · since 1990 · expires 2027-12-31 · University of Kansas School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$92,843
Medicare paid this office $92,843 for 364 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 185 | $32,278 | $106 |
| Long return visit (40+ min) | 114 | $27,640 | $154 |
| New patient visit (45+ min) | 78 | $10,247 | $131 |
| Short return visit (20+ min) | 77 | $6,961 | $76 |
| New patient visit (60+ min) | 27 | $4,883 | $181 |
See all 7 services
| Return visit (30+ min) | 185 | $32,278 | $106 |
| Long return visit (40+ min) | 114 | $27,640 | $154 |
| New patient visit (45+ min) | 78 | $10,247 | $131 |
| Short return visit (20+ min) | 77 | $6,961 | $76 |
| New patient visit (60+ min) | 27 | $4,883 | $181 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $820 | $29 |
| Short return visit | 15 | $777 | $52 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
364 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 18% · Women 53% · Also on Medicaid 36% · Health risk score 1.42. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Dementia 34% · Diabetes 33% · Chronic kidney disease 29% · Depression 28% · Coronary heart disease 20% · Atrial fibrillation 18% · Cancer 15% · Heart failure 14% · Stroke 13% · COPD 12%.
The office billed $334,762, Medicare allowed $131,331 and paid $92,843; for 847 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 364 | 847 | 77 | 1.42 | $334,762 | $92,843 |
| 2023 | 351 | 774 | 77 | 1.33 | $298,815 | $84,480 |
| 2022 | 365 | 721 | 76 | 1.41 | $285,324 | $82,977 |
| 2021 | 359 | 784 | 75 | 1.31 | $280,154 | $87,987 |
| 2020 | 320 | 726 | 74 | 1.60 | $237,676 | $69,730 |
| 2019 | 330 | 821 | 74 | 1.53 | $275,024 | $78,576 |
| 2018 | 270 | 596 | 76 | 1.58 | $195,666 | $58,129 |
| 2017 | 295 | 835 | 76 | 1.39 | $217,822 | $78,820 |
| 2016 | 280 | 754 | 76 | 1.48 | $182,949 | $71,354 |
| 2015 | 313 | 981 | 76 | 1.32 | $159,010 | $94,380 |
| 2014 | 317 | 785 | 76 | 1.18 | $127,145 | $74,126 |
| 2013 | 301 | 762 | 76 | 1.28 | $120,600 | $71,401 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 199 | $37,494 | $106 |
| Long return visit (40+ min) | 58 | $14,878 | $158 |
| New patient visit (45+ min) | 115 | $14,646 | $127 |
| Short return visit (20+ min) | 59 | $4,430 | $69 |
| New patient visit (60+ min) | 23 | $4,422 | $192 |
| Muscle electrical test | 11 | $1,412 | $94 |
2022: 8 services
| Return visit (30+ min) | 192 | $29,702 | $101 |
| Long return visit (40+ min) | 89 | $21,780 | $154 |
| New patient visit (45+ min) | 78 | $10,743 | $138 |
| New patient visit (60+ min) | 54 | $10,127 | $188 |
| Short return visit (20+ min) | 43 | $3,005 | $60 |
| Nerve test | 11 | $1,477 | $134 |
| Muscle electrical test | 13 | $1,259 | $90 |
| Short return visit | 11 | $407 | $37 |
2021: 8 services
| Return visit (30+ min) | 186 | $35,868 | $108 |
| New patient visit (45+ min) | 126 | $17,133 | $136 |
| Long return visit (40+ min) | 52 | $13,536 | $157 |
| Short return visit (20+ min) | 60 | $5,561 | $72 |
| New patient visit (60+ min) | 13 | $2,713 | $209 |
| Muscle electrical test | 19 | $2,379 | $103 |
| Nerve test | 13 | $1,641 | $126 |
| Short return visit | 16 | $879 | $55 |
2020: 8 services
| Return visit (30+ min) | 166 | $32,442 | $93 |
| New patient visit (45+ min) | 100 | $13,757 | $138 |
| Long return visit (40+ min) | 15 | $4,757 | $132 |
| Short return visit (20+ min) | 49 | $4,276 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,035 | $185 |
| Muscle electrical test | 17 | $1,774 | $93 |
| Nerve test | 12 | $1,467 | $122 |
| Measurement of brain wave activity (eeg), awake and drowsy | 11 | $598 | $54 |
2019: 7 services
| Return visit (30+ min) | 161 | $34,876 | $93 |
| New patient visit (45+ min) | 153 | $20,777 | $136 |
| Long return visit (40+ min) | 30 | $6,273 | $131 |
| Short return visit (20+ min) | 59 | $6,074 | $63 |
| Measurement of brain wave activity (eeg), awake and drowsy | 11 | $586 | $53 |
| Short return visit | 13 | $524 | $40 |
| Administration of influenza virus vaccine | 11 | $222 | $20 |
2018: 5 services
| Return visit (30+ min) | 148 | $25,947 | $86 |
| New patient visit (45+ min) | 104 | $14,287 | $137 |
| Short return visit (20+ min) | 46 | $3,827 | $64 |
| Long return visit (40+ min) | 22 | $3,096 | $135 |
| Measurement of brain wave activity (eeg), awake and drowsy | 16 | $841 | $53 |
2017: 5 services
| Return visit (30+ min) | 223 | $49,025 | $88 |
| New patient visit (45+ min) | 115 | $15,640 | $136 |
| Extended office or other outpatient service, first hour | 25 | $3,915 | $109 |
| Short return visit (20+ min) | 42 | $2,326 | $53 |
| Measurement of brain wave activity (eeg), awake and drowsy | 11 | $514 | $47 |
2016: 6 services
| Return visit (30+ min) | 184 | $36,099 | $88 |
| New patient visit (45+ min) | 75 | $10,844 | $145 |
| Short return visit (20+ min) | 81 | $5,658 | $57 |
| Long return visit (40+ min) | 20 | $2,787 | $107 |
| New patient visit (60+ min) | 14 | $2,280 | $163 |
| Exam of neurobehavioral status, first hour | 29 | $2,219 | $72 |
2015: 9 services
| Return visit (30+ min) | 206 | $44,962 | $89 |
| New patient visit (45+ min) | 116 | $15,419 | $133 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 12 | $7,878 | $219 |
| Short return visit (20+ min) | 83 | $6,815 | $59 |
| Long return visit (40+ min) | 23 | $4,057 | $123 |
| New patient visit (60+ min) | 22 | $3,650 | $166 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 13 | $2,878 | $63 |
| Exam of neurobehavioral status, first hour | 32 | $2,663 | $78 |
| Measurement of brain wave activity (eeg), awake and drowsy | 12 | $647 | $50 |
2014: 6 services
| Return visit (30+ min) | 196 | $39,481 | $86 |
| New patient visit (45+ min) | 130 | $17,435 | $134 |
| Short return visit (20+ min) | 60 | $4,436 | $57 |
| New patient visit (60+ min) | 13 | $2,236 | $172 |
| Long return visit (40+ min) | 14 | $1,789 | $128 |
| Measurement of brain wave activity (eeg), awake and drowsy | 15 | $707 | $47 |
2013: 6 services
| Return visit (30+ min) | 192 | $35,379 | $89 |
| New patient visit (45+ min) | 111 | $15,088 | $136 |
| Short return visit (20+ min) | 85 | $7,090 | $59 |
| Long return visit (40+ min) | 17 | $2,047 | $120 |
| Muscle electrical test | 11 | $871 | $73 |
| Measurement of brain wave activity (eeg), awake and drowsy | 13 | $637 | $49 |
Medicaid work
$409 in 2023
Medicaid paid $409 for 31 billed services this clinician did in 2023, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 31 | $409 |
| 2023 | 31 | 1 | 18 | $409 |
| 2022 | 13 | 1 | 13 | $96 |
| 2020 | 12 | 1 | 12 | $96 |
| 2018 | 14 | 1 | 14 | $432 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 13 | $96 |
2020
| Return visit (30+ min) | 12 | $96 |
2018
| New patient visit (45+ min) | 14 | $432 |
Drugs they prescribed that Part D paid
$610,521
Pharmacies billed $610,521 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,087) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
1,969 generic and 118 brand-name prescriptions · $610,521 in drug cost · 102 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nuplazid | Parkinson's psychosis | 30 | $179,704 | $5,990 |
| Teriflunomide | None | 25 | $138,474 | $5,539 |
| Rytary | Parkinson's | 16 | $32,548 | $2,034 |
| Rivastigmine | None | 70 | $11,917 | $170 |
| Carbidopa-Levodopa | None | 272 | $9,637 | $35 |
See all 35 drugs
| Nuplazid | Parkinson's psychosis | 30 | $179,704 | $5,990 |
| Teriflunomide | None | 25 | $138,474 | $5,539 |
| Rytary | Parkinson's | 16 | $32,548 | $2,034 |
| Rivastigmine | None | 70 | $11,917 | $170 |
| Carbidopa-Levodopa | None | 272 | $9,637 | $35 |
| Rasagiline Mesylate | None | 52 | $7,666 | $147 |
| Lacosamide | None | 41 | $5,644 | $138 |
| Memantine | None | 194 | $5,458 | $28 |
| Entacapone | None | 12 | $4,704 | $392 |
| Donepezil | None | 417 | $4,579 | $11 |
| Carbidopa-Levodopa Er | None | 47 | $2,806 | $60 |
| Galantamine Er | None | 29 | $2,802 | $97 |
| Levetiracetam | None | 54 | $2,047 | $38 |
| Divalproex Sodium Er | None | 21 | $1,610 | $77 |
| Pramipexole Dihydrochloride | None | 65 | $1,456 | $22 |
| Midodrine | None | 34 | $1,433 | $42 |
| Quetiapine | None | 64 | $1,264 | $20 |
| Trospium Chloride | None | 22 | $1,063 | $48 |
| Gabapentin | None | 64 | $1,056 | $17 |
| Ropinirole | None | 19 | $1,000 | $53 |
| Oxcarbazepine | None | 16 | $794 | $50 |
| Propranolol Hcl Er | None | 21 | $761 | $36 |
| Duloxetine | None | 13 | $758 | $58 |
| Baclofen | None | 12 | $674 | $56 |
| Mycophenolate Mofetil | None | 15 | $575 | $38 |
| Lamotrigine | None | 49 | $570 | $12 |
| Modafinil | None | 11 | $406 | $37 |
| Clonazepam | None | 46 | $394 | $9 |
| Fludrocortisone Acetate | None | 30 | $328 | $11 |
| Escitalopram | None | 29 | $304 | $10 |
| Propranolol | None | 16 | $267 | $17 |
| Atorvastatin | None | 13 | $206 | $16 |
| Lorazepam | None | 12 | $180 | $15 |
| Prednisone | None | 18 | $100 | $6 |
| Paroxetine | None | 12 | $44 | $4 |
Year by year
| 2024 | 2,087 | 276 | 0% (0) | 6% | $610,521 |
| 2023 | 1,759 | 245 | 0% (0) | 6% | $506,228 |
| 2022 | 1,628 | 245 | 0% (0) | None | $541,610 |
| 2021 | 1,695 | 219 | 0% (0) | None | $834,423 |
| 2020 | 1,852 | 195 | None | 13% | $1,104,965 |
| 2019 | 1,746 | 175 | None | 15% | $1,111,227 |
| 2018 | 1,701 | 208 | 0% (0) | 21% | $827,034 |
| 2017 | 2,472 | 231 | None | 24% | $1,210,370 |
| 2016 | 2,534 | 226 | None | 28% | $1,357,807 |
| 2015 | 2,551 | 232 | None | 31% | $1,370,793 |
| 2014 | 2,049 | 209 | None | None | $1,091,173 |
| 2013 | 2,052 | 235 | None | 39% | $687,510 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Austedo | None | 11 | $146,528 | $13,321 |
| Nuplazid | Parkinson's psychosis | 12 | $76,640 | $6,387 |
| Rasagiline Mesylate | None | 45 | $16,018 | $356 |
| Lacosamide | None | 44 | $15,506 | $352 |
| Carbidopa-Levodopa | None | 259 | $10,973 | $42 |
| Entacapone | None | 19 | $9,892 | $521 |
| Neupro | None | 11 | $8,477 | $771 |
| Memantine | None | 162 | $7,828 | $48 |
| Dalfampridine Er | None | 12 | $7,200 | $600 |
| Donepezil | None | 355 | $7,027 | $20 |
| Ropinirole | None | 12 | $5,242 | $437 |
| Rivastigmine | None | 22 | $5,059 | $230 |
| Carbidopa-Levodopa-Entacapone | None | 14 | $4,697 | $336 |
| Levetiracetam | None | 71 | $4,014 | $57 |
| Pramipexole Dihydrochloride | None | 54 | $2,643 | $49 |
| Gabapentin | None | 53 | $1,741 | $33 |
| Carbidopa-Levodopa Er | None | 33 | $1,736 | $53 |
| Lamotrigine | None | 53 | $1,523 | $29 |
| Galantamine Er | None | 22 | $1,290 | $59 |
| Divalproex Sodium Er | None | 26 | $1,231 | $47 |
| Trospium Chloride | None | 16 | $1,197 | $75 |
| Oxcarbazepine | None | 14 | $922 | $66 |
| Mycophenolate Mofetil | None | 12 | $871 | $73 |
| Clozapine | None | 34 | $844 | $25 |
| Duloxetine | None | 11 | $766 | $70 |
| Quetiapine | None | 43 | $755 | $18 |
| Rivastigmine | None | 11 | $749 | $68 |
| Bupropion Xl | None | 14 | $744 | $53 |
| Pregabalin | None | 15 | $590 | $39 |
| Pyridostigmine | None | 11 | $537 | $49 |
| Midodrine | None | 15 | $514 | $34 |
| Escitalopram | None | 26 | $353 | $14 |
| Prednisone | None | 27 | $202 | $7 |
| Lorazepam | None | 13 | $138 | $11 |
| Clonazepam | None | 31 | $114 | $4 |
2022: 28 drugs
| Nuplazid | Parkinson's psychosis | 23 | $104,876 | $4,560 |
| Vimpat | None | 28 | $30,759 | $1,099 |
| Rasagiline Mesylate | None | 48 | $22,514 | $469 |
| Nourianz | None | 13 | $21,318 | $1,640 |
| Lacosamide | None | 20 | $13,195 | $660 |
| Carbidopa-Levodopa | None | 222 | $9,700 | $44 |
| Memantine | None | 134 | $9,444 | $70 |
| Carbidopa-Levodopa-Entacapone | None | 13 | $5,165 | $397 |
| Rivastigmine | None | 15 | $4,905 | $327 |
| Donepezil | None | 317 | $4,809 | $15 |
| Levetiracetam | None | 51 | $3,780 | $74 |
| Pramipexole Dihydrochloride | None | 60 | $2,588 | $43 |
| Bupropion Xl | None | 20 | $1,896 | $95 |
| Galantamine Er | None | 20 | $1,866 | $93 |
| Trospium Chloride | None | 20 | $1,702 | $85 |
| Quetiapine | None | 42 | $1,652 | $39 |
| Gabapentin | None | 64 | $1,491 | $23 |
| Carbidopa-Levodopa Er | None | 30 | $1,481 | $49 |
| Ropinirole | None | 17 | $1,463 | $86 |
| Oxcarbazepine | None | 22 | $1,446 | $66 |
| Lamotrigine | None | 63 | $1,259 | $20 |
| Duloxetine | None | 18 | $1,043 | $58 |
| Divalproex Sodium Er | None | 19 | $1,015 | $53 |
| Baclofen | None | 11 | $678 | $62 |
| Galantamine Hbr | None | 12 | $560 | $47 |
| Clozapine | None | 14 | $296 | $21 |
| Escitalopram | None | 31 | $232 | $7 |
| Clonazepam | None | 34 | $171 | $5 |
2021: 36 drugs
| Northera | None | 13 | $254,733 | $19,595 |
| Nuplazid | Parkinson's psychosis | 31 | $126,132 | $4,069 |
| Nourianz | None | 38 | $70,216 | $1,848 |
| Vimpat | None | 33 | $31,156 | $944 |
| Rasagiline Mesylate | None | 64 | $24,510 | $383 |
| Nuedexta | None | 12 | $16,568 | $1,381 |
| Neupro | None | 19 | $13,437 | $707 |
| Exelon | None | 18 | $13,319 | $740 |
| Namzaric | None | 17 | $12,139 | $714 |
| Carbidopa-Levodopa | None | 231 | $11,604 | $50 |
| Carbidopa-Levodopa-Entacapone | None | 18 | $8,716 | $484 |
| Memantine | None | 116 | $5,654 | $49 |
| Ropinirole Er | None | 19 | $3,741 | $197 |
| Donepezil | None | 279 | $3,655 | $13 |
| Rivastigmine | None | 18 | $3,648 | $203 |
| Pramipexole Dihydrochloride | None | 52 | $3,003 | $58 |
| Memantine Hcl Er | None | 13 | $1,733 | $133 |
| Duloxetine | None | 44 | $1,460 | $33 |
| Carbidopa-Levodopa Er | None | 31 | $1,440 | $46 |
| Quetiapine | None | 25 | $1,396 | $56 |
| Trospium Chloride | None | 26 | $1,393 | $54 |
| Levetiracetam | None | 51 | $1,376 | $27 |
| Gabapentin | None | 61 | $1,362 | $22 |
| Divalproex Sodium Er | None | 28 | $1,348 | $48 |
| Lamotrigine | None | 54 | $1,205 | $22 |
| Bupropion Xl | None | 22 | $1,109 | $50 |
| Oxcarbazepine | None | 20 | $1,062 | $53 |
| Baclofen | None | 30 | $1,052 | $35 |
| Ropinirole | None | 24 | $989 | $41 |
| Clozapine | None | 16 | $788 | $49 |
| Galantamine Hbr | None | 12 | $160 | $13 |
| Clonazepam | None | 31 | $159 | $5 |
| Rivastigmine | None | 11 | $140 | $13 |
| Citalopram Hbr | None | 11 | $102 | $9 |
| Escitalopram | None | 13 | $102 | $8 |
| Atorvastatin | None | 11 | $37 | $3 |
2020: 37 drugs
| Northera | None | 29 | $508,167 | $17,523 |
| Nuplazid | Parkinson's psychosis | 36 | $136,828 | $3,801 |
| Rasagiline Mesylate | None | 88 | $49,245 | $560 |
| Rytary | Parkinson's | 17 | $40,885 | $2,405 |
| Nuedexta | None | 17 | $31,997 | $1,882 |
| Vimpat | None | 22 | $29,400 | $1,336 |
| Carbidopa-Levodopa-Entacapone | None | 28 | $12,681 | $453 |
| Namzaric | None | 14 | $10,143 | $725 |
| Carbidopa-Levodopa | None | 184 | $8,676 | $47 |
| Neupro | None | 12 | $8,237 | $686 |
| Rivastigmine | None | 22 | $4,608 | $209 |
| Pramipexole Dihydrochloride | None | 53 | $4,211 | $79 |
| Memantine | None | 130 | $4,066 | $31 |
| Trospium Chloride Er | None | 24 | $3,879 | $162 |
| Carbidopa-Levodopa Er | None | 81 | $3,586 | $44 |
| Ropinirole Er | None | 26 | $3,190 | $123 |
| Donepezil | None | 244 | $2,993 | $12 |
| Trospium Chloride | None | 29 | $2,668 | $92 |
| Memantine Hcl Er | None | 14 | $2,339 | $167 |
| Midodrine | None | 18 | $2,021 | $112 |
| Ropinirole | None | 50 | $1,893 | $38 |
| Gabapentin | None | 85 | $1,751 | $21 |
| Divalproex | None | 12 | $1,609 | $134 |
| Levetiracetam | None | 40 | $1,554 | $39 |
| Lamotrigine | None | 41 | $1,433 | $35 |
| Bupropion Xl | None | 34 | $1,268 | $37 |
| Baclofen | None | 34 | $1,104 | $32 |
| Duloxetine | None | 22 | $1,046 | $48 |
| Oxcarbazepine | None | 18 | $886 | $49 |
| Divalproex Sodium Er | None | 18 | $874 | $49 |
| Quetiapine | None | 43 | $725 | $17 |
| Galantamine Er | None | 11 | $691 | $63 |
| Escitalopram | None | 60 | $599 | $10 |
| Zonisamide | None | 13 | $504 | $39 |
| Clozapine | None | 13 | $391 | $30 |
| Clonazepam | None | 56 | $277 | $5 |
| Citalopram Hbr | None | 15 | $139 | $9 |
2019: 35 drugs
| Northera | None | 32 | $511,821 | $15,994 |
| Aubagio | None | 18 | $133,505 | $7,417 |
| Nuplazid | Parkinson's psychosis | 32 | $103,849 | $3,245 |
| Rasagiline Mesylate | None | 76 | $53,968 | $710 |
| Nuedexta | None | 15 | $24,778 | $1,652 |
| Vimpat | None | 16 | $21,362 | $1,335 |
| Memantine Hcl Er | None | 56 | $13,371 | $239 |
| Carbidopa-Levodopa-Entacapone | None | 30 | $13,021 | $434 |
| Pramipexole Er | None | 11 | $12,076 | $1,098 |
| Rivastigmine | None | 27 | $8,783 | $325 |
| Exelon | None | 12 | $8,303 | $692 |
| Carbidopa-Levodopa | None | 173 | $6,631 | $38 |
| Trospium Chloride Er | None | 30 | $4,229 | $141 |
| Pramipexole Dihydrochloride | None | 56 | $4,182 | $75 |
| Carbidopa-Levodopa Er | None | 81 | $3,956 | $49 |
| Ropinirole Er | None | 15 | $3,662 | $244 |
| Memantine | None | 77 | $3,567 | $46 |
| Donepezil | None | 238 | $2,973 | $12 |
| Levetiracetam | None | 37 | $2,399 | $65 |
| Mycophenolate Mofetil | None | 11 | $2,398 | $218 |
| Midodrine | None | 28 | $2,351 | $84 |
| Gabapentin | None | 77 | $2,020 | $26 |
| Divalproex Sodium Er | None | 25 | $1,596 | $64 |
| Ropinirole | None | 79 | $1,562 | $20 |
| Duloxetine | None | 15 | $1,523 | $102 |
| Lamotrigine | None | 46 | $1,347 | $29 |
| Oxcarbazepine | None | 28 | $1,262 | $45 |
| Rivastigmine | None | 18 | $1,166 | $65 |
| Divalproex | None | 24 | $1,097 | $46 |
| Escitalopram | None | 65 | $948 | $15 |
| Quetiapine | None | 35 | $744 | $21 |
| Baclofen | None | 32 | $714 | $22 |
| Bupropion Xl | None | 17 | $548 | $32 |
| Clonazepam | None | 37 | $241 | $7 |
| Citalopram Hbr | None | 26 | $164 | $6 |
2018: 41 drugs
| Northera | None | 12 | $172,347 | $14,362 |
| Aubagio | None | 15 | $104,207 | $6,947 |
| Nuplazid | Parkinson's psychosis | 34 | $98,108 | $2,886 |
| Rasagiline Mesylate | None | 84 | $70,721 | $842 |
| Nuedexta | None | 25 | $32,614 | $1,305 |
| Namzaric | None | 37 | $24,929 | $674 |
| Rytary | Parkinson's | 23 | $22,071 | $960 |
| Vimpat | None | 20 | $22,004 | $1,100 |
| Namenda Xr | None | 35 | $19,258 | $550 |
| Carbidopa-Levodopa-Entacapone | None | 27 | $18,203 | $674 |
| Memantine Hcl Er | None | 48 | $14,715 | $307 |
| Exelon | None | 16 | $10,435 | $652 |
| Rivastigmine | None | 22 | $10,433 | $474 |
| Neupro | None | 12 | $7,987 | $666 |
| Carbidopa-Levodopa | None | 163 | $6,369 | $39 |
| Trospium Chloride Er | None | 29 | $5,257 | $181 |
| Ropinirole Er | None | 20 | $4,236 | $212 |
| Pramipexole Dihydrochloride | None | 50 | $4,199 | $84 |
| Carbidopa-Levodopa Er | None | 53 | $3,798 | $72 |
| Midodrine | None | 42 | $3,460 | $82 |
| Memantine | None | 36 | $3,033 | $84 |
| Donepezil | None | 198 | $2,953 | $15 |
| Gabapentin | None | 56 | $2,771 | $49 |
| Mycophenolate Mofetil | None | 19 | $2,093 | $110 |
| Divalproex | None | 30 | $1,969 | $66 |
| Lamotrigine | None | 49 | $1,683 | $34 |
| Levetiracetam | None | 32 | $1,322 | $41 |
| Ropinirole | None | 36 | $851 | $24 |
| Oxcarbazepine | None | 13 | $808 | $62 |
| Baclofen | None | 34 | $799 | $23 |
| Rivastigmine | None | 13 | $773 | $59 |
| Quetiapine | None | 44 | $710 | $16 |
| Bupropion Xl | None | 14 | $710 | $51 |
| Amantadine | None | 15 | $671 | $45 |
| Trospium Chloride | None | 13 | $555 | $43 |
| Citalopram Hbr | None | 44 | $447 | $10 |
| Divalproex Sodium Er | None | 13 | $431 | $33 |
| Clonazepam | None | 37 | $411 | $11 |
| Escitalopram | None | 31 | $384 | $12 |
| Azathioprine | None | 12 | $339 | $28 |
| Primidone | None | 16 | $158 | $10 |
2017: 52 drugs
| Northera | None | 20 | $255,536 | $12,777 |
| Ampyra | None | 30 | $88,440 | $2,948 |
| Avonex | None | 13 | $88,272 | $6,790 |
| Rasagiline Mesylate | None | 81 | $78,589 | $970 |
| Namenda Xr | None | 111 | $64,609 | $582 |
| Copaxone | None | 11 | $64,120 | $5,829 |
| Nuplazid | Parkinson's psychosis | 26 | $60,965 | $2,345 |
| Vimpat | None | 46 | $42,316 | $920 |
| Rytary | Parkinson's | 28 | $31,678 | $1,131 |
| Rivastigmine | None | 66 | $27,831 | $422 |
| Namzaric | None | 45 | $26,703 | $593 |
| Carbidopa-Levodopa-Entacapone | None | 54 | $23,947 | $443 |
| Azilect | None | 15 | $16,087 | $1,072 |
| Neupro | None | 24 | $15,337 | $639 |
| Exelon | None | 14 | $10,900 | $779 |
| Nuedexta | None | 13 | $10,459 | $805 |
| Carbidopa-Levodopa | None | 240 | $9,299 | $39 |
| Trospium Chloride Er | None | 42 | $9,038 | $215 |
| Ropinirole Er | None | 19 | $8,718 | $459 |
| Memantine | None | 61 | $6,588 | $108 |
| Carbidopa-Levodopa Er | None | 65 | $4,401 | $68 |
| Donepezil | None | 296 | $4,385 | $15 |
| Pramipexole Dihydrochloride | None | 53 | $4,326 | $82 |
| Gabapentin | None | 90 | $2,706 | $30 |
| Mycophenolate Mofetil | None | 24 | $2,671 | $111 |
| Levetiracetam | None | 47 | $2,604 | $55 |
| Divalproex | None | 43 | $2,178 | $51 |
| Lamotrigine | None | 72 | $1,982 | $28 |
| Duloxetine | None | 27 | $1,889 | $70 |
| Amantadine | None | 17 | $1,652 | $97 |
| Bupropion Xl | None | 30 | $1,549 | $52 |
| Baclofen | None | 54 | $1,538 | $28 |
| Quetiapine | None | 71 | $1,285 | $18 |
| Trospium Chloride | None | 23 | $1,239 | $54 |
| Ropinirole | None | 47 | $1,091 | $23 |
| Midodrine | None | 21 | $910 | $43 |
| Oxcarbazepine | None | 18 | $876 | $49 |
| Escitalopram | None | 56 | $825 | $15 |
| Citalopram Hbr | None | 68 | $718 | $11 |
| Tizanidine | None | 14 | $438 | $31 |
| Fludrocortisone Acetate | None | 12 | $415 | $35 |
| Methylprednisolone Sodium Succ | None | 11 | $392 | $36 |
| Clonazepam | None | 33 | $375 | $11 |
| Azathioprine | None | 13 | $341 | $26 |
| Mirtazapine | None | 11 | $289 | $26 |
| Alprazolam | None | 12 | $271 | $23 |
| Trazodone | None | 12 | $257 | $21 |
| Eszopiclone | None | 15 | $201 | $13 |
| Potassium Chloride | None | 15 | $196 | $13 |
| Primidone | None | 12 | $155 | $13 |
| Nortriptyline | None | 18 | $109 | $6 |
| Prednisone | None | 17 | $98 | $6 |
2016: 54 drugs
| Northera | None | 16 | $166,760 | $10,422 |
| Azilect | None | 132 | $140,238 | $1,062 |
| Tecfidera | None | 20 | $124,138 | $6,207 |
| Avonex | None | 12 | $102,865 | $8,572 |
| Aubagio | None | 15 | $88,923 | $5,928 |
| Copaxone | None | 13 | $69,663 | $5,359 |
| Namenda Xr | None | 155 | $67,621 | $436 |
| Tetrabenazine | None | 11 | $60,896 | $5,536 |
| Ampyra | None | 21 | $55,417 | $2,639 |
| Rytary | Parkinson's | 38 | $37,522 | $987 |
| Rivastigmine | None | 78 | $29,034 | $372 |
| Exelon | None | 27 | $23,585 | $874 |
| Carbidopa-Levodopa-Entacapone | None | 80 | $21,604 | $270 |
| Neupro | None | 31 | $20,449 | $660 |
| Namzaric | None | 26 | $14,444 | $556 |
| Vimpat | None | 15 | $14,425 | $962 |
| Trospium Chloride Er | None | 74 | $11,992 | $162 |
| Stalevo 200 | None | 11 | $8,565 | $779 |
| Carbidopa-Levodopa | None | 259 | $7,575 | $29 |
| Entacapone | None | 17 | $6,199 | $365 |
| Memantine | None | 44 | $5,828 | $132 |
| Ropinirole Er | None | 11 | $5,433 | $494 |
| Levetiracetam | None | 91 | $3,842 | $42 |
| Pramipexole Dihydrochloride | None | 33 | $3,086 | $94 |
| Carbidopa-Levodopa Er | None | 65 | $2,979 | $46 |
| Donepezil | None | 235 | $2,662 | $11 |
| Divalproex | None | 34 | $2,321 | $68 |
| Galantamine Er | None | 13 | $2,248 | $173 |
| Gabapentin | None | 61 | $2,042 | $33 |
| Quetiapine | None | 73 | $1,581 | $22 |
| Mycophenolate Mofetil | None | 24 | $1,465 | $61 |
| Bupropion Xl | None | 42 | $1,445 | $34 |
| Amantadine | None | 22 | $1,420 | $65 |
| Trospium Chloride | None | 17 | $1,320 | $78 |
| Escitalopram | None | 60 | $1,113 | $19 |
| Lamotrigine | None | 57 | $1,067 | $19 |
| Baclofen | None | 38 | $945 | $25 |
| Duloxetine | None | 21 | $903 | $43 |
| Midodrine | None | 14 | $888 | $63 |
| Oxcarbazepine | None | 17 | $729 | $43 |
| Ropinirole | None | 39 | $641 | $16 |
| Fludrocortisone Acetate | None | 33 | $608 | $18 |
| Clonazepam | None | 15 | $559 | $37 |
| Citalopram Hbr | None | 80 | $544 | $7 |
| Trazodone | None | 27 | $508 | $19 |
| Tizanidine | None | 14 | $319 | $23 |
| Rizatriptan | None | 17 | $303 | $18 |
| Alprazolam | None | 22 | $297 | $13 |
| Mirtazapine | None | 15 | $218 | $15 |
| Zonisamide | None | 11 | $196 | $18 |
| Azathioprine | None | 13 | $157 | $12 |
| Fluoxetine | None | 15 | $145 | $10 |
| Primidone | None | 11 | $130 | $12 |
| Prednisone | None | 14 | $70 | $5 |
2015: 50 drugs
| Tecfidera | None | 26 | $158,146 | $6,083 |
| Avonex | None | 18 | $144,118 | $8,007 |
| Azilect | None | 161 | $130,726 | $812 |
| Northera | None | 13 | $115,440 | $8,880 |
| Exelon | None | 124 | $71,773 | $579 |
| Aubagio | None | 13 | $68,500 | $5,269 |
| Namenda Xr | None | 159 | $64,129 | $403 |
| Copaxone | None | 12 | $58,594 | $4,883 |
| Ampyra | None | 15 | $38,753 | $2,584 |
| Carbidopa-Levodopa-Entacapone | None | 55 | $31,349 | $570 |
| Neupro | None | 43 | $24,964 | $581 |
| Vimpat | None | 12 | $13,198 | $1,100 |
| Ropinirole Er | None | 15 | $12,747 | $850 |
| Rytary | Parkinson's | 11 | $12,143 | $1,104 |
| Namenda | None | 25 | $12,040 | $482 |
| Entacapone | None | 37 | $10,509 | $284 |
| Trospium Chloride Er | None | 52 | $8,697 | $167 |
| Carbidopa-Levodopa | None | 253 | $8,522 | $34 |
| Rivastigmine | None | 18 | $8,216 | $456 |
| Pramipexole Dihydrochloride | None | 57 | $4,070 | $71 |
| Donepezil | None | 279 | $4,003 | $14 |
| Carbidopa-Levodopa Er | None | 81 | $3,799 | $47 |
| Bupropion Xl | None | 63 | $2,902 | $46 |
| Levetiracetam | None | 70 | $2,411 | $34 |
| Divalproex | None | 37 | $2,392 | $65 |
| Modafinil | None | 12 | $2,216 | $185 |
| Gabapentin | None | 51 | $1,756 | $34 |
| Duloxetine | None | 26 | $1,710 | $66 |
| Amantadine | None | 19 | $1,615 | $85 |
| Quetiapine | None | 51 | $1,528 | $30 |
| Mycophenolate Mofetil | None | 27 | $1,337 | $50 |
| Trospium Chloride | None | 16 | $1,332 | $83 |
| Acetazolamide | None | 13 | $1,280 | $98 |
| Escitalopram | None | 43 | $990 | $23 |
| Citalopram Hbr | None | 109 | $989 | $9 |
| Lamotrigine | None | 47 | $932 | $20 |
| Baclofen | None | 52 | $798 | $15 |
| Ropinirole | None | 21 | $746 | $36 |
| Azathioprine | None | 21 | $589 | $28 |
| Fludrocortisone Acetate | None | 37 | $538 | $15 |
| Zonisamide | None | 16 | $438 | $27 |
| Oxcarbazepine | None | 17 | $406 | $24 |
| Fluoxetine | None | 22 | $270 | $12 |
| Trazodone | None | 18 | $261 | $14 |
| Topiramate | None | 13 | $205 | $16 |
| Pentoxifylline | None | 13 | $196 | $15 |
| Paroxetine | None | 18 | $184 | $10 |
| Clonazepam | None | 27 | $174 | $6 |
| Prednisone | None | 16 | $125 | $8 |
| Nortriptyline | None | 12 | $98 | $8 |
2014: 40 drugs
| Avonex | 28 | $169,300 | $6,046 |
| Azilect | 152 | $100,912 | $664 |
| Xenazine | 11 | $76,931 | $6,994 |
| Exelon | 166 | $75,945 | $457 |
| Namenda Xr | 139 | $45,567 | $328 |
| Carbidopa-Levodopa-Entacapone | 85 | $45,084 | $530 |
| Namenda | 65 | $28,944 | $445 |
| Neupro | 30 | $14,445 | $482 |
| Vimpat | 15 | $13,156 | $877 |
| Entacapone | 25 | $9,876 | $395 |
| Aggrenox | 16 | $7,833 | $490 |
| Carbidopa-Levodopa | 154 | $6,743 | $44 |
| Stalevo 200 | 11 | $6,414 | $583 |
| Duloxetine | 19 | $4,471 | $235 |
| Trospium Chloride Er | 16 | $4,132 | $258 |
| Donepezil | 205 | $3,203 | $16 |
| Mycophenolate Mofetil | 41 | $2,991 | $73 |
| Levetiracetam | 44 | $2,673 | $61 |
| Pramipexole Dihydrochloride | 55 | $2,201 | $40 |
| Divalproex | 29 | $2,114 | $73 |
| Carbidopa-Levodopa Er | 50 | $2,045 | $41 |
| Gabapentin | 57 | $1,803 | $32 |
| Lamotrigine | 62 | $1,373 | $22 |
| Acetazolamide | 12 | $1,027 | $86 |
| Ropinirole | 16 | $1,019 | $64 |
| Oxcarbazepine | 19 | $722 | $38 |
| Quetiapine | 27 | $673 | $25 |
| Baclofen | 17 | $512 | $30 |
| Fluoxetine | 21 | $488 | $23 |
| Bupropion Xl | 15 | $452 | $30 |
| Citalopram Hbr | 51 | $446 | $9 |
| Escitalopram | 18 | $428 | $24 |
| Azathioprine | 20 | $426 | $21 |
| Bupropion Hcl Sr | 19 | $392 | $21 |
| Prednisone | 23 | $321 | $14 |
| Zonisamide | 12 | $277 | $23 |
| Paroxetine | 13 | $173 | $13 |
| Clonazepam | 19 | $121 | $6 |
| Nortriptyline | 11 | $77 | $7 |
| Risperidone | 11 | $30 | $3 |
2013: 45 drugs
| Copaxone | 19 | $88,970 | $4,683 |
| Avonex | 11 | $77,652 | $7,059 |
| Exelon | 166 | $70,161 | $423 |
| Azilect | 98 | $59,590 | $608 |
| Namenda | 152 | $52,570 | $346 |
| Aubagio | 11 | $42,004 | $3,819 |
| Carbidopa-Levodopa-Entacapone | 104 | $38,826 | $373 |
| Modafinil | 17 | $26,361 | $1,551 |
| Stalevo 200 | 16 | $14,009 | $876 |
| Entacapone | 26 | $11,316 | $435 |
| Mirapex Er | 20 | $9,350 | $467 |
| Cymbalta | 16 | $7,921 | $495 |
| Aricept | 17 | $7,761 | $457 |
| Carbidopa-Levodopa | 114 | $7,219 | $63 |
| Lyrica | 22 | $6,361 | $289 |
| Donepezil | 203 | $5,098 | $25 |
| Mycophenolate Mofetil | 40 | $4,666 | $117 |
| Stalevo 150 | 13 | $4,542 | $349 |
| Neupro | 23 | $4,004 | $174 |
| Lunesta | 12 | $2,941 | $245 |
| Trospium Chloride Er | 13 | $2,915 | $224 |
| Levetiracetam | 47 | $2,404 | $51 |
| Gabapentin | 79 | $2,336 | $30 |
| Lamotrigine | 62 | $2,310 | $37 |
| Carbidopa-Levodopa Er | 57 | $2,306 | $40 |
| Ropinirole | 37 | $2,113 | $57 |
| Trospium Chloride | 16 | $2,022 | $126 |
| Divalproex | 27 | $1,823 | $68 |
| Divalproex Sodium Er | 18 | $1,324 | $74 |
| Pramipexole Dihydrochloride | 37 | $1,060 | $29 |
| Escitalopram | 26 | $788 | $30 |
| Fludrocortisone Acetate | 13 | $560 | $43 |
| Quetiapine | 23 | $558 | $24 |
| Oxcarbazepine | 11 | $538 | $49 |
| Primidone | 16 | $526 | $33 |
| Citalopram Hbr | 51 | $482 | $9 |
| Acetazolamide | 14 | $473 | $34 |
| Fluoxetine | 23 | $430 | $19 |
| Prednisone | 29 | $252 | $9 |
| Haloperidol | 11 | $171 | $16 |
| Baclofen | 21 | $150 | $7 |
| Clonazepam | 17 | $150 | $9 |
| Trazodone | 20 | $146 | $7 |
| Clonidine | 12 | $89 | $7 |
| Folic Acid | 12 | $73 | $6 |
Money from drug and device companies
$4,777 in 2025
| 2025 | 16 | 43 | $550 | $4,777 |
| 2024 | 18 | 35 | None | $2,604 |
| 2023 | 15 | 44 | $1,338 | $4,699 |
| 2022 | 14 | 45 | $3,393 | $6,475 |
| 2021 | 10 | 21 | $150 | $3,224 |
| 2020 | 15 | 27 | $1,305 | $2,843 |
| 2019 | 20 | 58 | $4,180 | $9,891 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| LivaNova USA | Vns Therapy | $1,633 | 5 payments
|
| Medtronic | Percept PC Brainsense | $738 | 14 payments
|
| Vertex Pharmaceuticals | None | $400 | 1 payment
|
| Argenx US | Vyvgart Hytrulo | $368 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $277 | 3 payments
|
| Abbvie | Vyalev | $257 | 5 payments
|
See all 43 published payments
| Abbvie | Meals · 2025-12-10 | Vyalev | $15 |
| Abbvie | Meals · 2025-12-10 | Vyalev | $10 |
| LivaNova USA | Meals · 2025-11-15 | Vns Therapy | $267 |
| LivaNova USA | Travel · 2025-11-14 | Vns Therapy | $367 |
| LivaNova USA | Travel · 2025-11-14 | Vns Therapy | $500 |
| LivaNova USA | Travel · 2025-11-14 | Vns Therapy | $324 |
| LivaNova USA | Meals · 2025-11-14 | Vns Therapy | $175 |
| TG Therapeutics | Meals · 2025-11-13 | Briumvi | $140 |
| Abbvie | Meals · 2025-11-12 | Vyalev | $105 |
| Argenx US | Meals · 2025-10-31 | Vyvgart Hytrulo | $138 |
| Argenx US | Meals · 2025-10-30 | Vyvgart Hytrulo | $150 |
| Medtronic | Travel · 2025-09-24 | Percept PC Brainsense | $9 |
| Medtronic | Travel · 2025-09-23 | Percept PC Brainsense | $3 |
| Medtronic | Travel · 2025-09-20 | Percept PC Brainsense | $52 |
| Medtronic | Travel · 2025-09-20 | Percept PC Brainsense | $92 |
| Medtronic | Meals · 2025-09-20 | Percept PC Brainsense | $114 |
| Medtronic | Meals · 2025-09-20 | Percept PC Brainsense | $84 |
| Medtronic | Meals · 2025-09-20 | Percept PC Brainsense | $31 |
| Medtronic | Travel · 2025-09-19 | Percept PC Brainsense | $48 |
| Medtronic | Travel · 2025-09-19 | Percept PC Brainsense | $98 |
| Medtronic | Travel · 2025-09-19 | Percept PC Brainsense | $9 |
| Medtronic | Travel · 2025-09-19 | Percept PC Brainsense | $8 |
| Medtronic | Travel · 2025-09-19 | Percept PC Brainsense | $143 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-18 | Wainua | $126 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-09-10 | Rexulti | $97 |
| Medtronic | Travel · 2025-08-25 | Percept PC Brainsense | $35 |
| Abbvie | Meals · 2025-08-06 | Vyalev | $100 |
| Genentech | Meals · 2025-07-17 | Ocrevus | $33 |
| EMD Serono | Meals · 2025-07-16 | Mavenclad | $111 |
| Alexion Pharmaceuticals | Meals · 2025-07-08 | None | $68 |
| Biogen | Consulting · 2025-06-16 | Tysabri | $150 |
| MDD US Operations | Meals · 2025-06-13 | None | $124 |
| MDD US Operations | Meals · 2025-06-10 | None | $16 |
| Ucb | Meals · 2025-06-05 | Nayzilam | $63 |
| Alexion Pharmaceuticals | Meals · 2025-05-22 | Ultomiris | $132 |
| Supernus Pharmaceuticals | Meals · 2025-05-17 | None | $70 |
| Ucb | Meals · 2025-05-14 | Nayzilam | $50 |
| Amgen | Meals · 2025-04-24 | Uplizna | $124 |
| Abbvie | Meals · 2025-04-08 | Vyalev | $28 |
| Argenx US | Meals · 2025-04-08 | Vyvgart Hytrulo | $81 |
| Alexion Pharmaceuticals | Meals · 2025-04-05 | Ultomiris | $77 |
| Medtronic | Meals · 2025-03-19 | Percept PC Brainsense | $11 |
| Vertex Pharmaceuticals | Consulting · 2025-03-13 | None | $400 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,604
| Medtronic | Percept PC Brainsense | $565 | 9 payments
|
| Alexion Pharmaceuticals | Ultomiris | $317 | 3 payments
|
| Lilly USA | Kisunla | $170 | 2 payments
|
| Genzyme | None | $147 | 2 payments
|
| EMD Serono | Mavenclad | $144 | 1 payment
|
| Amgen | Uplizna | $124 | 1 payment
|
| Ucb | Zilbrysq | $124 | 1 payment
|
| Abbvie | Vyalev | $115 | 3 payments
|
| Catalyst Pharmaceuticals | Fycompa | $114 | 1 payment
|
| Amneal Pharmaceuticals | Crexont | $112 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $111 | 1 payment
|
| Biogen | None | $99 | 1 payment
|
| Axsome Therapeutics | Auvelity | $98 | 1 payment
|
| Argenx US | Vyvgart Hytrulo | $96 | 2 payments
|
| Genentech | Ocrevus | $93 | 3 payments
|
| Neurelis | Valtoco | $87 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | Rexulti | $62 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $25 | 1 payment
|
2023: $4,699
| Medtronic | Percept PC Brainsense | $1,435 | 15 payments
|
| Argenx US | Vyvgart | $1,402 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $277 | 3 payments
|
| Biogen | Tysabri | $246 | 2 payments
|
| AbbVie | Qulipta | $239 | 3 payments
|
| Horizon Therapeutics plc | Uplizna | $188 | 3 payments
|
| Lilly USA | Amyvid | $173 | 2 payments
|
| Genzyme | None | $133 | 1 payment
|
| SK Life Science | Xcopri | $130 | 4 payments
|
| Otsuka America Pharmaceutical | Rexulti | $116 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Rexulti | $98 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $97 | 1 payment
|
| Ucb | None | $79 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $52 | 2 payments
|
| Genentech | Ocrevus | $34 | 1 payment
|
2022: $6,475
| Biogen | Aduhelm | $3,457 | 6 payments
|
| Medtronic | Percept PC Brainsense | $1,309 | 18 payments
|
| Alnylam Pharmaceuticals | None | $387 | 1 payment
|
| Horizon Therapeutics plc | Uplizna | $182 | 3 payments
|
| Genzyme | Aubagio | $180 | 3 payments
|
| Boston Scientific | General - Dbs | $175 | 2 payments
|
| Lilly USA | Amyvid | $173 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $163 | 2 payments
|
| Novartis Pharmaceuticals | Kesimpta | $151 | 2 payments
|
| SK Life Science | Xcopri | $107 | 1 payment
|
| Argenx US | None | $76 | 1 payment
|
| Acorda Therapeutics | Inbrija | $50 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $48 | 2 payments
|
| Abbvie | Ubrelvy | $20 | 1 payment
|
2021: $3,224
| Boston Scientific | Vercise | $1,535 | 7 payments
|
| LivaNova USA | Vns - Sentiva | $700 | 3 payments
|
| Biogen | Tysabri | $333 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $124 | 1 payment
|
| Genzyme | None | $124 | 1 payment
|
| Kyowa Kirin | Nourianz | $119 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $85 | 1 payment
|
| AbbVie | Duopa | $78 | 1 payment
|
| EMD Serono | None | $77 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $49 | 2 payments
|
2020: $2,843
| Kyowa Kirin | Nourianz | $1,429 | 2 payments
|
| Alexion Pharmaceuticals | Soliris | $350 | 3 payments
|
| Medtronic USA | Activa | $179 | 5 payments
|
| Boston Scientific | General - Dbs | $170 | 2 payments
|
| Biogen | Tysabri | $165 | 3 payments
|
| Akcea Therapeutics | Tegsedi | $121 | 1 payment
|
| Genzyme | Aubagio | $115 | 1 payment
|
| EMD Serono | Mavenclad | $84 | 2 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $82 | 2 payments
|
| LivaNova USA | Vns Therapy | $42 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $26 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $20 | 1 payment
|
| Sunovion Pharmaceuticals | Kynmobi | $20 | 1 payment
|
| AbbVie | Duopa | $20 | 1 payment
|
| Adamas Pharmaceuticals | Gocovri | $19 | 1 payment
|
2019: $9,891
| Lundbeck | Northera | $3,923 | 6 payments
|
| Medtronic USA | Activa | $2,018 | 14 payments
|
| LivaNova USA | Vns Therapy | $1,330 | 6 payments
|
| Alexion Pharmaceuticals | Soliris | $718 | 8 payments
|
| Boston Scientific | Spectra Wavewriter | $319 | 2 payments
|
| Sunovion Pharmaceuticals | Aptiom | $243 | 2 payments
|
| EMD Serono | Mavenclad | $234 | 3 payments
|
| Abbott Laboratories | Infinity Dbs Pulse Generators | $144 | 2 payments
|
| Genentech USA | Ocrevus | $128 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $124 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $119 | 1 payment
|
| Acorda Therapeutics | Inbrija | $118 | 1 payment
|
| Novartis Pharmaceuticals | None | $118 | 1 payment
|
| Shire North American Group | Gammagard Liquid | $93 | 1 payment
|
| Biogen | Tysabri | $80 | 2 payments
|
| AbbVie | Duopa | $60 | 3 payments
|
| Ucb | Briviact | $50 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $31 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $21 | 1 payment
|
| Genentech | Ocrevus | $21 | 1 payment
|
Professional record
- NPI
- 1982691705
- Licence
- CA G68739California G68739: Current · expires 2027-12-31
- Trained
- University of Kansas School of Med (Kc/Wich/Sal), 1988 · 38 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA GR0017862
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2005-10-06
- NPI last updated
- 2019-05-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2850 Telegraph Ave Ste 110, Berkeley, CA, 94705 · 20101 Lake Chabot Rd Fl 4, Castro Valley, CA, 94546